Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    TG Therapeutics Inc.

    NASDAQ: TGTX · Real-Time Price · USD
    36.72
    0.43 (1.18%)
    At close: Jul 03, 2025, 3:25 PM
    37.00
    0.76%
    After-hours: Jul 03, 2025, 04:42 PM EDT

    TG Therapeutics Statistics

    Share Statistics

    TG Therapeutics has 158.75M shares outstanding. The number of shares has increased by 2.54% in one year.

    Shares Outstanding

    n/a
    		 158.75M

    Shares Change (YoY)

    n/a
    		 2.54%

    Shares Change (QoQ)

    n/a
    		 1.07%

    Owned by Institutions (%)

    n/a
    		 66.8%

    Shares Floating

    n/a
    		 142.87M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,599

    FTD / Avg. Volume

    n/a
    		 0.07%

    Short Selling Information

    The latest short interest is 23.7M, so 14.93% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 23.7M

    Short % of Shares Out

    n/a
    		 14.93%

    Short % of Float

    n/a
    		 19.52%

    Short Ratio (days to cover)

    n/a
    		 12.78

    Valuation Ratios

    The PE ratio is 187.06 and the forward PE ratio is 20.7. TG Therapeutics's PEG ratio is 2.36.

    PE Ratio

    n/a
    		 187.06

    Forward PE

    n/a
    		 20.7

    PS Ratio

    n/a
    		 13.29

    Forward PS

    n/a
    		 3.6

    PB Ratio

    n/a
    		 19.67

    P/FCF Ratio

    n/a
    		 -107.84

    PEG Ratio

    n/a
    		 2.36
    Financial Ratio History

    Enterprise Valuation

    TG Therapeutics has an Enterprise Value (EV) of 4.45B.

    EV / Sales

    n/a
    		 13.52

    EV / EBITDA

    n/a
    		 89.15

    EV / EBIT

    n/a
    		 -109.79

    EV / FCF

    n/a
    		 -109.67

    Financial Position

    The company has a current ratio of 6.25, with a Debt / Equity ratio of 1.14.

    Current Ratio

    n/a
    		 6.25

    Quick Ratio

    n/a
    		 5.03

    Debt / Equity

    n/a
    		 1.14

    Debt / EBITDA

    n/a
    		 5.1

    Debt / FCF

    n/a
    		 -6.27

    Interest Coverage

    n/a
    		 1.75

    Financial Efficiency

    Return on Equity is 10.52% and Return on Invested Capital is 7.84%.

    Return on Equity

    n/a
    		 10.52%

    Return on Assets

    n/a
    		 4.05%

    Return on Invested Capital

    n/a
    		 7.84%

    Revenue Per Employee

    n/a
    		 $934,670.45

    Profits Per Employee

    n/a
    		 $66,428.98

    Employee Count

    n/a
    		 352

    Asset Turnover

    n/a
    		 0.57

    Inventory Turnover

    n/a
    		 0.35

    Taxes

    Income Tax

    n/a
    		 2.21M

    Effective Tax Rate

    n/a
    		 8.64%

    Stock Price Statistics

    The stock price has increased by 95.42% in the last 52 weeks. The beta is 1.94, so TG Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.94

    52-Week Price Change

    n/a
    		 95.42%

    50-Day Moving Average

    n/a
    		 37.04

    200-Day Moving Average

    n/a
    		 32.69

    Relative Strength Index (RSI)

    n/a
    		 50.43

    Average Volume (20 Days)

    n/a
    		 2,426,175

    Income Statement

    In the last 12 months, TG Therapeutics had revenue of 329M and earned 23.38M in profits. Earnings per share was 0.16.

    Revenue

    n/a
    		 329M

    Gross Profit

    n/a
    		 290.52M

    Operating Income

    n/a
    		 41.93M

    Net Income

    n/a
    		 23.38M

    EBITDA

    n/a
    		 49.9M

    EBIT

    n/a
    		 49.62M

    Earnings Per Share (EPS)

    n/a
    		 0.16
    Full Income Statement

    Balance Sheet

    The company has 179.89M in cash and 254.38M in debt, giving a net cash position of -74.49M.

    Cash & Cash Equivalents

    n/a
    		 179.89M

    Total Debt

    n/a
    		 254.38M

    Net Cash

    n/a
    		 -74.49M

    Retained Earnings

    n/a
    		 -1.53B

    Total Assets

    n/a
    		 656.69M

    Working Capital

    n/a
    		 484.3M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -40.52M and capital expenditures -45K, giving a free cash flow of -40.56M.

    Operating Cash Flow

    n/a
    		 -40.52M

    Capital Expenditures

    n/a
    		 -45K

    Free Cash Flow

    n/a
    		 -40.56M

    FCF Per Share

    n/a
    		 -0.28
    Full Cash Flow Statement

    Margins

    Gross margin is 88.3%, with operating and profit margins of 12.74% and 7.11%.

    Gross Margin

    n/a
    		 88.3%

    Operating Margin

    n/a
    		 12.74%

    Pretax Margin

    n/a
    		 7.78%

    Profit Margin

    n/a
    		 7.11%

    EBITDA Margin

    n/a
    		 15.17%

    EBIT Margin

    n/a
    		 12.74%

    FCF Margin

    n/a
    		 -12.33%

    Dividends & Yields

    TGTX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 0.53%

    FCF Yield

    n/a
    		 -0.93%
    Dividend Details

    Analyst Forecast

    The average price target for TGTX is $43, which is 17.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $43

    Price Target Difference

    n/a
    		 17.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 2.35

    Graham Upside

    n/a
    		 -93.6%

    Stock Splits

    The last stock split was on Apr 30, 2012. It was a backward split with a ratio of 4:225.

    Last Split Date

    n/a
    		 Apr 30, 2012

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 4:225

    Scores

    Altman Z-Score

    n/a
    		 6.69

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist